Disclosed are methods for treating one or more mammalian cancers, and in particular, methods for treating human breast cancer employing one or more iNOS pathway-inhibitory compounds, either alone, or in combination with one or more selected antihypertensive agents, including calcium channel antagonists, either alone, and further in combination with one or more conventional chemotherapeutic or anti-cancer regimens. Also disclosed are particular therapeutic formulations including these compositions, and methods for their use in treating refractory, metastatic, and relapsed cancers, and for managing or reversing treatment resistance in human triple-negative breast cancers in particular.
